Chardan Capital Maintains Sell on Mesoblast, Lowers Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae maintains a Sell rating on Mesoblast (NASDAQ:MESO) and lowers the price target from $2.5 to $2.
May 30, 2023 | 11:32 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Chardan Capital maintains a Sell rating on Mesoblast and lowers the price target from $2.5 to $2.
The lowered price target by Chardan Capital indicates a bearish outlook on Mesoblast's stock. This news is directly related to the company and is likely to have a negative impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100